Label Image (Lbl500901123)
Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-1123
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-1123). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Spl-divalproex-figure-1 (Spl Divalproex Figure 1)
This text provides information about two studies involving the medications PBO and DVPX, with the first study using the YMRS scale and the second study using the MRS scale.*
Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
This text provides a graph presenting the reduction in the CPS rate with the DVPX and placebo treatments. The graph shows the percentage of patients experiencing improvement, no change, or worsening in their condition. The percentages range from -100% to 100%, with specific values such as 0%, 25%, 50%, and 75% indicated for comparison between the two treatments.*
Spl-divalproex-figure-3 (Spl Divalproex Figure 3)
The text provides a description of a figure showing data related to "Buiuasiop" and "Juawanodw" with a section indicating "No Change." The figure appears to represent percentages related to patients. Further details or context would be needed for a more specific analysis.*
Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
Spl-divalproex-structure (Spl Divalproex Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
